Seeking Alpha

stephenhandal

stephenhandal
Send Message
View as an RSS Feed
View stephenhandal's Comments BY TICKER:
Latest  |  Highest rated
  • Today's Non-Move By FDA Tells Us One Thing... [View instapost]
    $25+ now? You were saying high $30s months ago, even low $40s at one point. Then that price dropped back to mid $30s, then $28-32 and now you're claiming $25+??
    Apr 16 09:41 AM | 2 Likes Like |Link to Comment
  • Amarin Vascepa Sales Data Misleading [View instapost]
    I don't think you understand, I don't have an issue with your previous predictions and such, but more with your arrogance/ego. You act like your current view has been your main view for Amarin for a long time. It hasn't. Furthermore, you feel that you have the right to censor comments and delete them. Then you act like you're the true and almighty God on Amarin. Come to terms. You think I'm an enemy. I'm not. I am also long with a very substantial position.
    Mar 27 01:38 PM | Likes Like |Link to Comment
  • Vascepa Scripts Likely Much Higher Than Early IMS Report [View instapost]
    "Using web analytics you will learn that 47% of visitors to the site stay there and visit multiple pages. They visit for at least 2 minutes."

    "These metrics far exceed industry averages."

    - What are industry averages? Sorry, I'm not familiar with the exact numbers. Could you please brief me on them? Thanks so much
    Mar 27 01:30 PM | Likes Like |Link to Comment
  • Amarin's 'All-In' On Vascepa Makes It A Massive Risk [View article]
    Thanks Jerry. I appreciate it. It's a battleground over there with him and his followers. It's hard to believe that Amarin has a 6 in front of its share price right now. Good luck. I think in the long run we'll be alright, but short-term, it's ugly.
    Mar 26 06:58 PM | Likes Like |Link to Comment
  • Amarin's 'All-In' On Vascepa Makes It A Massive Risk [View article]
    "The Marine launch has little if any bearing on the future of AMRN" - This is a completely false statement. The Marine launch is very important. Right now especially in the next 4-6 months, all that matters is sales. We need to see a rapid script uptake contrary to what you believe. If Amarin doesn't get its act together, then plan for this stock to take even a further beating. Everything else is sideline (combo, NCE and such). If Amarin wants to get acquired or partnered by the ANCHOR indication, then surely larger pharmaceutical companies are watching the launch closely. I can't believe you would say that. Then not to mention, saying that the Marine launch essentially isn't important would totally contradict your previous line of thinking that there would be a BO before 2013. Then you accuse Quoth the Raven of deception - that's wrong. You keep on acting like ANCHOR is the big prize when you were never talking about it previously.
    Mar 26 01:42 PM | 2 Likes Like |Link to Comment
  • Amarin Vascepa Sales Data Misleading [View instapost]
    Trolin, if they were 30-days, then why aren't our script numbers at 4-5k like Steve said? That should have happened already. I tend to think we'll have a clearer picture by May.
    Mar 25 01:09 PM | 2 Likes Like |Link to Comment
  • Amarin: Is The Trend Still Your Friend? [View article]
    Brian, you may have wanted to wait until next week to publish this because of sales numbers on Monday (possible sample conversion to prescriptions could be starting) and there's the FDA OB update on Friday... I'm not the author though. Good luck.
    Mar 8 06:23 PM | 4 Likes Like |Link to Comment
  • A Top Biotech Stock To Own In 2013 [View article]
    Also, I found a comment under Adam's article (we'll just leave the person who wrote the comment as anonymous) who listed some of Steve's previous calls which I thought were somewhat interesting:

    Oct. 12th 2012: "near 100% chance of near-term buyout. Near term is before 2012 end, specifically 15-30 days or less."

    Nov. 15th 2012: "hearing orange book determination coming this round... hang on folks"

    Nov. 16th 2012: "My views have not changed, NCE, near term BO +$30, and we could hear Monday still on NCE this month"

    Nov. 28th 2012: "I see no signs of salesforce being hired."

    Dec. 11th 2012: "Yazz: all due respect, let's get something straight. I dont cheerlead or pump AMRN."

    I'm not going to criticize Steve, as these comments purely speak for themselves, but as illustrated you can see for yourselves...
    Mar 8 04:43 PM | 1 Like Like |Link to Comment
  • Amarin: Liking This Speculative Stock's Risk-Reward Ratio [View article]
    6799, I just don't think Amarin is "highly risky".. It may be risky, but at this point, quite a bit would half to happen in order to really crash the stock. I am not on the side that the price would go down if we're denied NCE. I'm in the camp that any decision is good. Also, this article is a soft-bash, so that's part of my reasoning.
    Mar 6 11:07 PM | Likes Like |Link to Comment
  • Amarin: Liking This Speculative Stock's Risk-Reward Ratio [View article]
    You refer to Amarin as a "highly risky equity." Would you care to explain more? Sure Amarin is risky, but definitely not any riskier than some of the other biotechs.

    Also, you said you're a non-invasive cardiologist. What kind of procedures do you do and also what types of cholesterol-lowering drugs do you prescribe?
    Mar 6 07:26 PM | 1 Like Like |Link to Comment
  • A Top Biotech Stock To Own In 2013 [View article]
    Steve, I'll admit - you proved me wrong and published your article..

    Now, I'm still wondering though about your comment regarding the partnership. How do you know as a fact that Amarin turned that down? I highly doubt anyone besides the senior management has any idea.
    Mar 6 06:47 PM | Likes Like |Link to Comment
  • The Price May Be Increasing For An Amarin Buyout [View article]
    Amrnbagholder,

    There is nothing to look forward to from Steve except for another article. He knows nothing more than we do. I followed some of Steve's comments back in October/November and was somewhat optimistic about a buyout as a result of his BO speculation, but now have come to terms with realism. A buyout WILL NOT happen until ANCHOR is either very close to being approved or has been approved. Also we're going to need good sales. NCE will not do it, contrary to what Steve has said. I do think there is a good chance that they'll be a buyout by the end of 2013, but don't bet on it.

    In the short term, NCE and combo results should move stock up, but I still don't expect a buyout till later in the year. Good luck. Also management has been way too unclear and has added to the uncertainty. There is still great risk regardless of what others say. Even if the scripts are increasing every week, with no news, I can see the shorts pushing this down to low 7s.
    Mar 4 08:24 PM | 2 Likes Like |Link to Comment
  • Amarin Q4 Call Leaves A Fishy Taste In My Mouth [View article]
    No, we won't have to partner. I think Amarin should be able to get to $20-25 easily with ANCHOR approval, combo results, and NCE decision as well as some strong Marine sales. This will take a while, but it will happen. Then factor in BO premium and you're at $30..
    Mar 3 08:19 PM | 1 Like Like |Link to Comment
  • Amarin Q4 Call Leaves A Fishy Taste In My Mouth [View article]
    Steve, nice to know that you continue to pass over my comments:

    You said this recently: "Also, for a FACT, Amarin has rejected more than one partnership deal. This is not the course they want to go."

    Where's the evidence? I sure don't see any, otherwise you must have insider information. Please let me know.
    Mar 2 12:13 AM | Likes Like |Link to Comment
  • Amarin's Vascepa: 5 Myths Debunked [View article]
    I agree with most of what you said, but I wouldn't read into the line by line stuff too much. Overall, I think you summed it up: there wasn't much optimism so to speak relative to previous ones. It's going to take time as opposed to the "near term buyout" that someone purported - I wonder whom, oh I must have forgotten.........

    Amarin management isn't in a panic, but I'm sure they're pissed off at the their recent share price performance (or maybe not because they sure don't seem to care). I sure can say that it seemed like Joe "deflected" quite a few questions and was very careful in terms of not getting into any "active discussions" or deep into NCE talk.

    PS: I highly doubt you've listened to thousands of CCs and even hundreds is a stretch. I call BS.
    Mar 1 02:27 AM | Likes Like |Link to Comment
COMMENTS STATS
187 Comments
86 Likes